Literature DB >> 19098006

Annular protofibrils are a structurally and functionally distinct type of amyloid oligomer.

Rakez Kayed1, Anna Pensalfini, Larry Margol, Yuri Sokolov, Floyd Sarsoza, Elizabeth Head, James Hall, Charles Glabe.   

Abstract

Amyloid oligomers are believed to play causal roles in several types of amyloid-related neurodegenerative diseases. Several different types of amyloid oligomers have been reported that differ in morphology, size, or toxicity, raising the question of the pathological significance and structural relationships between different amyloid oligomers. Annular protofibrils (APFs) have been described in oligomer preparations of many different amyloidogenic proteins and peptides as ring-shaped or pore-like structures. They are interesting because their pore-like morphology is consistent with numerous reports of membrane-permeabilizing activity of amyloid oligomers. Here we report the preparation of relatively homogeneous preparations of APFs and an antiserum selective for APFs (alphaAPF) compared with prefibrillar oligomers (PFOs) and fibrils. PFOs appear to be precursors for APF formation, which form in high yield after exposure to a hydrophobic-hydrophilic interface. Surprisingly, preformed APFs do not permeabilize lipid bilayers, unlike the precursor PFOs. APFs display a conformation-dependent, generic epitope that is distinct from that of PFOs and amyloid fibrils. Incubation of PFOs with phospholipids vesicles results in a loss of PFO immunoreactivity with a corresponding increase in alphaAPF immunoreactivity, suggesting that lipid vesicles catalyze the conversion of PFOs into APFs. The annular anti-protofibril antibody also recognizes heptameric alpha-hemolysin pores, but not monomers, suggesting that the antibody recognizes an epitope that is specific for a beta barrel structural motif.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19098006      PMCID: PMC2640961          DOI: 10.1074/jbc.M808591200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  45 in total

1.  Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease.

Authors:  C A McLean; R A Cherny; F W Fraser; S J Fuller; M J Smith; K Beyreuther; A I Bush; C L Masters
Journal:  Ann Neurol       Date:  1999-12       Impact factor: 10.422

2.  Molecular crowding accelerates fibrillization of alpha-synuclein: could an increase in the cytoplasmic protein concentration induce Parkinson's disease?

Authors:  Mark D Shtilerman; Tomas T Ding; Peter T Lansbury
Journal:  Biochemistry       Date:  2002-03-26       Impact factor: 3.162

Review 3.  Expression of normal sequence pathogenic proteins for neurodegenerative disease contributes to disease risk: 'permissive templating' as a general mechanism underlying neurodegeneration.

Authors:  J Hardy
Journal:  Biochem Soc Trans       Date:  2005-08       Impact factor: 5.407

4.  Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease.

Authors:  L F Lue; Y M Kuo; A E Roher; L Brachova; Y Shen; L Sue; T Beach; J H Kurth; R E Rydel; J Rogers
Journal:  Am J Pathol       Date:  1999-09       Impact factor: 4.307

5.  Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate.

Authors:  D M Walsh; A Lomakin; G B Benedek; M M Condron; D B Teplow
Journal:  J Biol Chem       Date:  1997-08-29       Impact factor: 5.157

6.  Protofibrillar islet amyloid polypeptide permeabilizes synthetic vesicles by a pore-like mechanism that may be relevant to type II diabetes.

Authors:  Magdalena Anguiano; Richard J Nowak; Peter T Lansbury
Journal:  Biochemistry       Date:  2002-09-24       Impact factor: 3.162

7.  Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice.

Authors:  Lauren M Billings; Salvatore Oddo; Kim N Green; James L McGaugh; Frank M LaFerla
Journal:  Neuron       Date:  2005-03-03       Impact factor: 17.173

8.  Surfactant properties of Alzheimer's A beta peptides and the mechanism of amyloid aggregation.

Authors:  B Soreghan; J Kosmoski; C Glabe
Journal:  J Biol Chem       Date:  1994-11-18       Impact factor: 5.157

9.  Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: detection of amyloid aggregation in solution.

Authors:  H LeVine
Journal:  Protein Sci       Date:  1993-03       Impact factor: 6.725

10.  Lipids revert inert Abeta amyloid fibrils to neurotoxic protofibrils that affect learning in mice.

Authors:  Ivo Cristiano Martins; Inna Kuperstein; Hannah Wilkinson; Elke Maes; Mieke Vanbrabant; Wim Jonckheere; Patrick Van Gelder; Dieter Hartmann; Rudi D'Hooge; Bart De Strooper; Joost Schymkowitz; Frederic Rousseau
Journal:  EMBO J       Date:  2007-12-06       Impact factor: 11.598

View more
  124 in total

1.  Preparation and characterization of toxic Abeta aggregates for structural and functional studies in Alzheimer's disease research.

Authors:  Asad Jan; Dean M Hartley; Hilal A Lashuel
Journal:  Nat Protoc       Date:  2010-06-03       Impact factor: 13.491

2.  β-Barrel topology of Alzheimer's β-amyloid ion channels.

Authors:  Hyunbum Jang; Fernando Teran Arce; Srinivasan Ramachandran; Ricardo Capone; Ratnesh Lal; Ruth Nussinov
Journal:  J Mol Biol       Date:  2010-10-21       Impact factor: 5.469

3.  Two different binding modes of α-synuclein to lipid vesicles depending on its aggregation state.

Authors:  Tobias Högen; Johannes Levin; Felix Schmidt; Mario Caruana; Neville Vassallo; Hans Kretzschmar; Kai Bötzel; Frits Kamp; Armin Giese
Journal:  Biophys J       Date:  2012-04-03       Impact factor: 4.033

4.  An equilibrium model for linear and closed-loop amyloid fibril formation.

Authors:  Shuo Yang; Michael D W Griffin; Katrina J Binger; Peter Schuck; Geoffrey J Howlett
Journal:  J Mol Biol       Date:  2012-02-24       Impact factor: 5.469

Review 5.  Biochemistry of amyloid β-protein and amyloid deposits in Alzheimer disease.

Authors:  Colin L Masters; Dennis J Selkoe
Journal:  Cold Spring Harb Perspect Med       Date:  2012-06       Impact factor: 6.915

6.  Measurement of the attachment and assembly of small amyloid-β oligomers on live cell membranes at physiological concentrations using single-molecule tools.

Authors:  Suman Nag; Jiji Chen; J Irudayaraj; S Maiti
Journal:  Biophys J       Date:  2010-09-22       Impact factor: 4.033

7.  Human cytomegalovirus UL97 kinase prevents the deposition of mutant protein aggregates in cellular models of Huntington's disease and ataxia.

Authors:  Cristy Tower; Lianwu Fu; Rachel Gill; Mark Prichard; Mathieu Lesort; Elizabeth Sztul
Journal:  Neurobiol Dis       Date:  2010-08-20       Impact factor: 5.996

8.  A yeast toxic mutant of HET-s((218-289)) prion displays alternative intermediates of amyloidogenesis.

Authors:  Karine Berthelot; Sophie Lecomte; Julie Géan; Françoise Immel; Christophe Cullin
Journal:  Biophys J       Date:  2010-08-09       Impact factor: 4.033

9.  Structural determination of Abeta25-35 micelles by molecular dynamics simulations.

Authors:  Xiang Yu; Qiuming Wang; Jie Zheng
Journal:  Biophys J       Date:  2010-07-21       Impact factor: 4.033

Review 10.  Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks.

Authors:  Jorge J Palop; Lennart Mucke
Journal:  Nat Neurosci       Date:  2010-07       Impact factor: 24.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.